Views On Healthcare Trust of America Inc. (HTA) From A Technical Perspective

The stock of Healthcare Trust of America Inc. (NYSE:HTA) increased by $0.42 on Tuesday to finish at $29.70, up 1.43 percent. The last five days have seen an average of 2,296,480 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$3.69. The average number of shares traded over the last 20 days was 4,332,150, while the average volume over the last 50 days totaled 3,677,464.

HTA stock dropped -5.35% since last month. On 05/10/22, the company’s shares reached a one-month low of $28.06. The stock touched a high of $34.83 on 01/04/22, after rallying from a low of $26.36 in 52 weeks. The price of HTA stock has declined by -11.05% or -$3.69 this year, reaching a new high 2 times. Still, the stock price is down -14.72% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Valuation Metrics

Healthcare Trust of America Inc. (HTA) has a trailing price-to-earnings (P/E) ratio of 71.05. Beta for the stock is 0.63. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 8.63, the price-to-book (PB) ratio of 2.12, and the price-to-cash flow ratio of 250.27.

Company paid $0.3250 per share in dividends, remained unchanged from $0.3250 last year. A $0.0050 dividend increase was reported on Tuesday August 3 2021.

Financial Health

As far as profitability goes, gross margin for the trailing twelve months is 68.70% percent. Healthcare Trust of America Inc.’s operating margin stood at 19.40% for the same period. Based on annual data, it had gross profit of $153.34 million and revenue of $767.07 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. HTA’s return on assets (ROA) during the last 12 months has been 1.40%. There was a 2.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 3.00%.

Earnings Surprise

According to Healthcare Trust of America Inc.’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $202.0 million, while revenues rose by 5.2% to $195.7 million. It was predicted that Healthcare Trust of America Inc.’s quarterly earnings would be $0.08, but it ended up being $0.1. EBITDA was $113.13 million for the quarter. At the end of Healthcare Trust of America Inc.’s most recent quarter ended March 30, its total debt was $3.25 billion. Equity owned by shareholders amounts to $229.08 million.

Technical Picture

Here’s a quick look at Healthcare Trust of America Inc.’s (HTA) price momentum from a technical perspective. As of 24 May, the RSI 9-day stood at 53.91%, suggesting the stock is Neutral, with a 21.65% historical volatility rate.

The stochastic %K and %D were 61.33% and 42.62% respectively, while the average true range (ATR) was 0.76. Based on the 14-day stochastic reading of 84.58%, the RSI (14) reading is 49.63%. On the 9-day MACD Oscillator, the stock is at 0.17, and the 14-day reading is at 0.17.

Analyst Ratings

In its most recent analyst report, Berenberg raised its rating on Healthcare Trust of America Inc. (NYSE: HTA) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Healthcare Trust of America Inc. (HTA) an Overweight rating. HTA is a stock that is recommended for selling by 0 brokerage firms, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 2 others recommend it as a buy.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam